Finally, an anti-NKG2C/IL-15/anti-CD33 TriKE construct was produced by Chiu and colleagues in order to target CD33+ AML cells with NKG2C+ CMV-reactivated patient-derived PB-NK cells but also NKG2C-engineered iPSC-derived NK cells [94]. This evidence concerns the gene CD33 and acute myeloid leukemia.